Brief: Esperion Therapeutics Closes Acquisition Of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)
02/04/2026 22:24
April 2 (Reuters) - Esperion Therapeutics Inc ESPR.O: ESPERION THERAPEUTICS CLOSES ACQUISITION OF CORSTASIS THERAPEUTICS, EXPANDING ITS CARDIOVASCULAR FRANCHISE WITH ENBUMYST™ (BUMETANIDE NASAL SPRAY) Source text: ID:nGNX694rpZ Further company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi